The effect of the endothelin receptor antagonist atrasentan on insulin resistance in phenotypic clusters of patients with type 2 diabetes and chronic kidney disease
Atrasentan significantly improved insulin sensitivity in patients with T2D and CKD, especially in those characterized by high insulin resistance (SIRD cluster). Further studies are warranted to investigate the long-term clinical outcomes of atrasentan treatment in these distinct phenotypic clusters.
Authors
- Hiddo J.L. Heerspink (ORCID: https://orcid.org/0000-0002-3126-3730)
- Maria F. Gomez (ORCID: https://orcid.org/0000-0001-6210-3142)
- J. David Smeijer (ORCID: https://orcid.org/0000-0003-1725-9927)
- Peter R Rossing (ORCID: https://orcid.org/0000-0002-1531-4294)
Institutions
- University of Copenhagen (DK)
- University Medical Center Groningen (NL)
- Steno Diabetes Centers (DK)
- University of Groningen (NL)
- Lund University (SE)
- The George Institute for Global Health (AU)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-11-06
- DOI
- https://doi.org/10.1111/dom.16041
- Citations
- 7
- Primary Topic
- Regulation of Appetite and Obesity
- Type
- article
- Field-Weighted Citation Impact
- 1.92
Funders
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Gilead Sciences
- Alexion Pharmaceuticals
- Steno Diabetes Center Copenhagen
- Innovative Health Initiative
- Stiftelsen för Strategisk Forskning
- Hjärt-Lungfonden
- Novo Nordisk
- Vetenskapsrådet
- Astellas Pharma
- Vifor Pharma